Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Toyama Chemical Applies For Approval Of Pediatric Antimicrobial Agent

This article was originally published in PharmAsia News

Executive Summary

Toyama Chemical applied for approval of Ozex powder for pediatric use. A newquinolone antimicrobial agent, the drug is indicated to treat pediatric pneumonia and otitis media. Ozex pediatric is based on the Ozex tablet that was developed and launched by the company in 1990. Toyama Chemical changed the tablet into powder for easier adjustment in dosage. Upon approval, Ozex pediatric will be the first newquinolone antimicrobial agent to treat pediatric pneumonia in Japan. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts